CARISMA Therapeutics Inc (CARM)
1.01
+0.02
(+2.27%)
USD |
NASDAQ |
Sep 27, 16:00
1.00
-0.01
(-0.99%)
After-Hours: 20:00
CARISMA Therapeutics Total Liabilities (Quarterly): 58.98M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 58.98M |
| March 31, 2024 | 62.90M |
| December 31, 2023 | 63.02M |
| September 30, 2023 | 60.49M |
| June 30, 2023 | 66.31M |
| Date | Value |
|---|---|
| March 31, 2023 | 70.06M |
| December 31, 2022 | 214.82M |
| June 30, 2022 | 97.54M |
| December 31, 2021 | 9.425M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
9.425M
Minimum
Dec 2021
214.82M
Maximum
Dec 2022
78.17M
Average
63.02M
Median
Dec 2023
Total Liabilities (Quarterly) Benchmarks
| EyePoint Pharmaceuticals Inc | 95.94M |
| Cassava Sciences Inc | 54.59M |
| Adverum Biotechnologies Inc | 85.77M |
| Regenxbio Inc | 221.11M |
| Editas Medicine Inc | 152.79M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 59.34M |
| Shareholders Equity (Quarterly) | 0.36M |
| Current Ratio | 3.248 |